Clinical trial NCT04365517: The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
Official title: The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Covid19
Diabetes Mellitus, Type 2
CKD
Lead sponsor: University of Milan
Sponsor class: OTHER
First posted: 2020-04-28
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A randomized controlled open label intervention study is proposed. Patients hospitalized for COVID-19 and suffering from type 2 diabetes will be included in the study and divided into two groups by randomization: sitagliptin add-on therapy with nutritional therapy with or without insulin (study group) vs nutritional therapy with or without insulin (group of control, standard therapy)
Primary purpose: TREATMENT

Brief summary: The COVID-19 pathology is frequently associated with diabetes mellitus and metabolic syndrome. In the epidemic outbreak that exploded at the beginning of 2020 in the Lombardy Region, about two thirds of the patients who died from COVID-19 were affected by diabetes mellitus. COVID-19 occurs in 70% of cases with an inflammatory pathology of the airways that can be fed by a cytokine storm and result in severe respiratory failure (10% cases) and death (5%). The pathophysiological molecular mechanisms are currently not clearly defined. It is hypothesized that the transmembrane glycoprotein type II CD26, known for the enzyme activity Dipeptilpeptidase 4 of the extracellular domain, may play a main role in this condition. It is in fact considerably expressed at the level of parenchyma and pulmonary interstitium and carries out both systemic and paracrine enzymatic activity, modulating the function of various proinflammatory cytokines, growth factors and vasoactive peptides in the deep respiratory tract. Of particular interest is the fact that Dipeptilpeptidase 4 has been identified as a cellular receptor for S glycoprotein of MERS-COV. In the case of the SARS-COV 2 virus, the main receptor is the Angiotensin-Converting Enzyme 2 protein, but a possible interaction with Dipeptilpeptidase 4 also cannot be excluded. The selective blockade of Dipeptilpeptidase 4 could therefore favorably modulate the pulmonary inflammatory response in the subject affected by COVID-19. This protein is also known for the enzymatic degradation function of the native glucagon-like peptide 1, one of the main regulators of insulin secretion. This is why it is a molecular target in the treatment of diabetes (drugs that selectively inhibit Dipeptilpeptidase 4 are marketed with an indication for the treatment of type 2 diabetes). It is believed that the use of a Dipeptilpeptidase 4 inhibitor in people with diabetes and hospitalized for Covid-19 may be safe and of particular interest for an evaluation of the effects on laboratory and instrumental indicators of inflammatory lung disease. Among the drugs that selectively block Dipeptilpeptidase 4, the one with the greatest affinity is Sitagliptin.

Detailed description: The investigators propose a randomized controlled open label intervention study. Patients hospitalized for COVID-19 and affected by type 2 diabetes mellitus will be included in the study and divided into two groups by randomization: sitagliptin add-on standard of care therapy with nutritional therapy with or without insulin treatment (study group) vs nutritional therapy with or without insulin treatment (group of control, standard therapy). The design of the study provides an open randomization to allow its feasibility in times compatible with the achievement of adequate cases during the epidemic. The presence of placebo and a double-blind study, would lead to longer planning and enrollment times.

Patients with type 2 diabetes mellitus hospitalized for COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin treatment. Patients with stage IV and V renal impairment (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded. Enrolled patients will be followed according to the following scheme:

Time points:

* T0: The doctor explains the protocol to the patient and he gives to him the informed consent and the letter to the general practitioner.
* T1: The patient gives the signed and dated consent and officially enters the study. Basic assessments will be made. At the baseline, the clinical response, the main laboratory and instrumental tests will be taken into consideration. Biological samples will be taken for immunological study. Diabetic patients will begin treatment with Sitagliptin 100 or 50 mg add-on to nutritional therapy and, eventually, insulin treatment. Any other hypoglycemic agents taken before admission will be suspended.
* T2: 7 days after T1, for both groups of patients, evaluation of the clinical response, of the average daily blood glucose levels, of the main laboratory and instrumental tests.
* T3: 10 days after T2, for both groups of patients, evaluation of clinical response, average daily blood glucose levels, of the main laboratory and instrumental tests. Collection of biological samples for immunological study. End of the study.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of type 2 diabetes, according to ADA 2020 criteria
* HbA1c levels at the entrance or in the two previous months \<9%
* Diagnosis of Covid-19 (swab for positive SARS-COV2 RNA) with pneumonia, with or without increase in inflammation indexes, with or without respiratory failure
* No indication for tocilizumab therapy (BCRSS, Brescia Covid Respiratory Severity Scale, \<3).
* Written and dated informed consent from the patient or his legally valid representative

Exclusion Criteria:

* Pregnancy
* Type 1 diabetes
* Stage IV and V renal failure (stimated glomerular filtration rate \<30 ml / min)
* Treatment with Dipeptidyl peptidase-4 inhibitors or GLP-1 Receptor Agonists in the month prior to hospitalization
* Pioglitazone treatment in the month prior to hospitalization
* Treatment in the month preceding or in the course of hospitalization with "biological" drugs for immuno-rheumatological diseases (in particular tocilizumab)
* Presence of other acute or chronic ongoing infections
* Neurological or psychiatric diseases, diagnosis of hemoglobinopathy, diagnosis of liver disease, cancer, cystic fibrosis or malabsorption syndrome
* Dysphagia with need for artificial nutrition
* Positive history of acute and chronic pancreatitis
* Unstable cardiovascular disease or known atherosclerotic disease
* A history of alcohol or drug abuse
* Known human immunodeficiency virus (HIV) or hepatitis
* Presence of serious diseases or conditions that make the patient unsuitable for the study
* Surgery in the previous two weeks

Primary outcomes:
measure: Time for clinical improvement
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Biochemical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameters of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Clinical parameter of acute lung disease
timeFrame: 1 month
measure: Biochemical parameter of acute lung disease
timeFrame: 1 month
measure: Biochemical parameter of acute lung disease
timeFrame: 1 month
measure: Biochemical parameter of acute lung disease
timeFrame: 1 month
measure: Biochemical parameter of acute lung disease
timeFrame: 1 month
measure: Biochemical parameter of acute lung disease
timeFrame: 1 month
Secondary outcomes:
measure: Dipeptilpeptidase 4 expression in biological samples
timeFrame: 6 months
measure: Cytokine-inflammatory profile
timeFrame: 6 months
measure: Glycemic variability
timeFrame: 1 month
measure: Glycemic variability
timeFrame: 1 month
measure: Cytokine-inflammatory profile
timeFrame: 6 months
measure: Cytokine-inflammatory profile
timeFrame: 6 months
measure: Cytokine-inflammatory profile
timeFrame: 6 months
measure: Cytokine-inflammatory profile
timeFrame: 6 months
measure: Cytokine-inflammatory profile
timeFrame: 6 months
Other outcomes:
Locations:
city: Milan
country: Italy
facility: ASST FBF Sacco
Study officials:
affiliation: University of Milan
name: Paolo Fiorina, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, Sun GZ, Yang GR, Zhang XL, Wang L, Xu X, Xu XP, Chan JC. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006 Jun;23(6):623-8. doi: 10.1111/j.1464-5491.2006.01861.x.
citation: Perlman S, Azhar EI, Memish ZA, Hui DS, Zumla A. Confronting the persisting threat of the Middle East respiratory syndrome to global health security. Lancet Infect Dis. 2020 Feb;20(2):158-160. doi: 10.1016/S1473-3099(19)30347-0. Epub 2019 Jul 3. No abstract available.
citation: Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.
citation: Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
citation: Zou H, Zhu N, Li S. The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease. Expert Opin Ther Targets. 2020 Feb;24(2):147-153. doi: 10.1080/14728222.2020.1721468. Epub 2020 Jan 31.
citation: Meyerholz DK, Lambertz AM, McCray PB Jr. Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol. 2016 Jan;186(1):78-86. doi: 10.1016/j.ajpath.2015.09.014. Epub 2015 Nov 18.
citation: Ikeda T, Kumagai E, Iwata S, Yamakawa A. Soluble CD26/Dipeptidyl Peptidase IV Enhances the Transcription of IL-6 and TNF-alpha in THP-1 Cells and Monocytes. PLoS One. 2013 Jun 21;8(6):e66520. doi: 10.1371/journal.pone.0066520. Print 2013.
citation: Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013 Mar 14;495(7440):251-4. doi: 10.1038/nature12005.
citation: Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3. No abstract available.
citation: Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020 Mar 17;9(1):601-604. doi: 10.1080/22221751.2020.1739565. eCollection 2020.
citation: Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019 Oct 17;4(20):e131774. doi: 10.1172/jci.insight.131774.
citation: Li K, Wohlford-Lenane CL, Channappanavar R, Park JE, Earnest JT, Bair TB, Bates AM, Brogden KA, Flaherty HA, Gallagher T, Meyerholz DK, Perlman S, McCray PB Jr. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):E3119-E3128. doi: 10.1073/pnas.1619109114. Epub 2017 Mar 27.